Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a report issued on Monday morning.

Other research analysts also recently issued reports about the company. Stephens began coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They set an overweight rating and a $25.00 price objective for the company. Cantor Fitzgerald reiterated an overweight rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. Finally, HC Wainwright restated a buy rating and set a $50.00 price objective on shares of Actinium Pharmaceuticals in a research report on Friday, July 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $11.43.

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock opened at $2.41 on Monday. Actinium Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $10.24. The firm has a market cap of $71.78 million, a PE ratio of -1.41 and a beta of 0.20.

Actinium Pharmaceuticals (NYSE:ATNM) last released its earnings results on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. As a group, equities analysts expect that Actinium Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several institutional investors have recently modified their holdings of ATNM. Sanders Morris Harris LLC purchased a new stake in Actinium Pharmaceuticals during the 1st quarter valued at $78,000. Virtu Financial LLC raised its stake in shares of Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after acquiring an additional 62,459 shares during the period. Rhumbline Advisers lifted its holdings in shares of Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after acquiring an additional 7,525 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after purchasing an additional 19,035 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after purchasing an additional 82,113 shares during the last quarter. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.